Stockreport

Larimar Therapeutics Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024 [Yahoo! Finance]

Larimar Therapeutics, Inc.  (LRMR) 
PDF Modeling and simulation predict that, in most patients with FA, 50 mg of nomlabofusp administered daily is likely to achieve FXN levels that are = 50% of levels observe [Read more]